Kim TM - Search Results

1

Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers.

Kim HS, Kim CG, Kim WK, Kim KA, Yoo J, Min BS, Paik S, Shin SJ, Lee H, Lee K, Kim H, Shin EC, Kim TM, Ahn JB. Kim HS, et al. Among authors: kim h, kim cg, kim wk, kim ka, kim tm. Front Cell Infect Microbiol. 2023 Mar 7;13:1101291. doi: 10.3389/fcimb.2023.1101291. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36960042 Free PMC article.

2

GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, Min B, Shin H, Kim TM, Heo DS, Hwang YK, Shin EC. Lim O, et al. Among authors: kim tm. PLoS One. 2013;8(1):e53611. doi: 10.1371/journal.pone.0053611. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326467 Free PMC article.

3

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.

Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ. Jung M, et al. Among authors: kim tm. Cancer Res Treat. 2017 Jan;49(1):44-53. doi: 10.4143/crt.2016.024. Epub 2016 Apr 27. Cancer Res Treat. 2017. PMID: 27121719 Free PMC article.

4

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Si L, et al. Among authors: kim tm. Eur J Cancer. 2020 Aug;135:31-38. doi: 10.1016/j.ejca.2020.04.044. Epub 2020 Jun 10. Eur J Cancer. 2020. PMID: 32534242 Clinical Trial.

5

Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values.

Kim AR, Choi KS, Kim MS, Kim KM, Kang H, Kim S, Chowdhury T, Yu HJ, Lee CE, Lee JH, Lee ST, Won JK, Kim JW, Kim YH, Kim TM, Park SH, Choi SH, Shin EC, Park CK. Kim AR, et al. Among authors: kim yh, kim km, kim ms, kim s, kim tm, kim jw. Cancer Immunol Immunother. 2021 Jul;70(7):1995-2008. doi: 10.1007/s00262-020-02836-w. Epub 2021 Jan 8. Cancer Immunol Immunother. 2021. PMID: 33416947 Free PMC article.

6

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.

Kim CG, Kim M, Hwang J, Kim ST, Jung M, Kim KH, Kim KH, Chang JS, Koom WS, Roh MR, Chung KY, Kim TM, Kim SK, Lee J, Shin SJ. Kim CG, et al. Among authors: kim st, kim m, kim sk, kim tm, kim kh. J Am Acad Dermatol. 2022 Nov;87(5):989-996. doi: 10.1016/j.jaad.2022.07.057. Epub 2022 Sep 6. J Am Acad Dermatol. 2022. PMID: 36068115

7

Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Kim KH, Kim TM, Go H, Kim WY, Jeon YK, Lee SH, Kim DW, Khwarg SI, Kim CW, Heo DS. Kim KH, et al. Among authors: kim wy, kim dw, kim cw, kim tm. Cancer Sci. 2011 Nov;102(11):1972-6. doi: 10.1111/j.1349-7006.2011.02051.x. Epub 2011 Sep 6. Cancer Sci. 2011. PMID: 21812857 Free article.

8

An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK. Nam SJ, et al. Among authors: kim cw, kim tm. Leuk Lymphoma. 2014 Nov;55(11):2466-76. doi: 10.3109/10428194.2013.879713. Epub 2014 Mar 3. Leuk Lymphoma. 2014. PMID: 24397616

9

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.

Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Ock CY, et al. Among authors: kim dw, kim s, kim m, kim tm. Clin Cancer Res. 2016 May 1;22(9):2261-70. doi: 10.1158/1078-0432.CCR-15-2834. Epub 2016 Jan 27. Clin Cancer Res. 2016. PMID: 26819449

10

Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.

Kim S, Kwon D, Koh J, Nam SJ, Kim YA, Kim TM, Kim CW, Jeon YK. Kim S, et al. Among authors: kim cw, kim ya, kim tm. Virchows Arch. 2020 Jul;477(1):131-142. doi: 10.1007/s00428-020-02790-z. Epub 2020 Mar 13. Virchows Arch. 2020. PMID: 32170448

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

670 results

Search Page